Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

(2010) D. Yecies et al.   BLOOD

KITmutations confer a distinct gene expression signature in core binding factor leukaemia

(2010) Sonja C. Lück et al.   BRITISH JOURNAL OF HAEMATOLOGY

cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production

(2010) N Vanlangenakker et al.   CELL DEATH AND DIFFERENTIATION

Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

(2010) C. A. Pratilas et al.   CLINICAL CANCER RESEARCH

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

(2010) Wyndham H Wilson et al.   LANCET ONCOLOGY

Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines

(2010) S. K. Tahir et al.   MOLECULAR CANCER THERAPEUTICS

cIAP1, cIAP2, and XIAP Act Cooperatively via Nonredundant Pathways to Regulate Genotoxic Stress-Induced Nuclear Factor- B Activation

(2009) H.-S. Jin et al.   CANCER RESEARCH

RIPK1 is not essential for TNFR1-induced activation of NF-κB

(2009) W W-L Wong et al.   CELL DEATH AND DIFFERENTIATION

An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer

(2009) G. Liu et al.   CLINICAL CANCER RESEARCH

An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently

(2009) J. Viaud et al.   MOLECULAR CANCER THERAPEUTICS

The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs

(2009) L. M. High et al.   MOLECULAR PHARMACOLOGY

PAK signaling in oncogenesis

(2009) P R Molli et al.   ONCOGENE

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

(2008) S. M. O'Brien et al.   BLOOD

Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer

(2008) C. L. Hann et al.   CANCER RESEARCH

Microtubule dynamics as a target in oncology

(2008) April L. Risinger et al.   CANCER TREATMENT REVIEWS

Bcl-2 inhibitors: small molecules with a big impact on cancer therapy

(2008) M Vogler et al.   CELL DEATH AND DIFFERENTIATION

Molecular characterization of acute myeloid leukemia

(2008) K. Dohner et al.   HAEMATOLOGICA

Inhibitor of apoptosis proteins in hematological malignancies

(2008) S Fulda   LEUKEMIA

cIAP1 and cIAP2 Facilitate Cancer Cell Survival by Functioning as E3 Ligases that Promote RIP1 Ubiquitination

(2008) Mathieu J.M. Bertrand et al.   MOLECULAR CELL

IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-κB as well as cell survival and oncogenesis

(2008) Mads Gyrd-Hansen et al.   NATURE CELL BIOLOGY

IAP-targeted therapies for cancer

(2008) E C LaCasse et al.   ONCOGENE

Core Binding Factor Acute Myeloid Leukemia

(2008) Peter Paschka   SEMINARS IN ONCOLOGY